Compelling evidence shows that SGLT2i also reduces CKD progression in non-diabetic patients with variable degrees of proteinuria, suggesting that SGLT2 activation is involved in CKD pathogenesis irrespective of its diabetes status [11]. This evidence concerns the gene SLC5A2 and chronic kidney disease.